尽管Merck Sharp和Dohme主动提议,新西兰卫生部仍封锁了早期获得癌症药物Keyturda的渠道。 New Zealand's Health NZ blocks early access to cancer drug Keytruda, despite Merck Sharp and Dohme's offer.

新西兰的癌症群体对NZ健康组织决定阻止及早获得癌症药物Keyturda感到失望。 Cancer groups in New Zealand are frustrated and disappointed with Health NZ's decision to block early access to the cancer drug Keytruda. Merck Sharp和Dohme提出在10月1日药物全额供资开始之前向20-30名病人提供免费治疗,但新西兰卫生部却阻止了这一点,援引了该药物的国家实施计划。 Merck Sharp and Dohme offered to provide free access to 20-30 patients before the drug's full funding begins on Oct. 1, but Health NZ prevented this, citing a national implementation plan for the drug. 癌症组织认为,这种拖延可能影响病人获得治疗的资格,因为有些人在过渡期间可能得到的效果较差的治疗。 Cancer organizations argue that this delay may affect patients' eligibility for the treatment, as some may receive less effective treatments in the interim.

August 04, 2024

8 文章